Serial 98537469
Live / Allowed — Second extension granted (statement of use) (as of 15 May 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 May 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98537469
- Mark type
- Design / logo
- Filed
- 07 May 2024
- Published for opposition
- 25 Mar 2025
- Attorney of record
- Christina Licursi
Goods and services
- Class 001 — Chemicals: Biological and chemical agents for scientific use other than for medical use, namely, addressable and programmable protein-based therapeutics
- Class 005 — Pharmaceuticals: Biological therapeutics, namely, addressable and programmable protein-based therapeutics, including multi-specific polypeptide-based therapeutics, namely, therapeutic pharmaceuticals for the treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders; pharmaceutical preparations, namely, addressable and programmable protein-based therapeutics, for treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders
- Class 042 — Scientific and technological services: Drug development services, namely, pharmaceutical drug development services; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products, namely, pharmaceutical drug development services; pharmaceutical and biotech research and development, namely, pharmaceutical drug development services
Owner
- Ampersand Biomedicines, Inc., Cambridge, MA, US
- Ampersand Biomedicines, Inc., Cambridge, MA, US
Prosecution history
- 16 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 May 2026 — SOU EXTENSION 2 GRANTED
- 15 May 2026 — SOU EXTENSION 2 FILED
- 15 May 2026 — SOU TEAS EXTENSION RECEIVED
- 20 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Nov 2025 — SOU EXTENSION 1 GRANTED
- 19 Nov 2025 — SOU EXTENSION 1 FILED
- 19 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 20 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Mar 2025 — PUBLISHED FOR OPPOSITION
- 19 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 21 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE